ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the main phase of its 200 patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, today announces unaudited results for the year ended 30 April 2019.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that the first phase of its ovarian cancer clinical verification study has reported positive results.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce positive results from its Parsortix FDA clinical study for metastatic breast cancer.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that its ParsortixTM system has been utilised in further groundbreaking new cancer research which demonstrates for the first time the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs.
ANGLE plc (AIM:AGL), a world-leading liquid biopsy company, is pleased to announce that top US cancer centre, the University of Texas MD Anderson Cancer Center has developed a new technique for assessing the metastatic potential of breast cancer using ANGLE’s ParsortixTM system.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that ethics approval has been obtained from the University of Rochester Medical Center Wilmot Cancer Institute for its ovarian cancer clinical verification study.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet), Duesseldorf, an interdisciplinary team of researchers and clinicians whose goal is to better understand systemic disease in cancer and to improve individualised therapy in cancer patients, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.
ANGLE plc (AIM:AGL), a world-leading liquid biopsy company, is delighted to announce that its ParsortixTMsystem has been utilised in further ground-breaking cancer research into CTC clusters demonstrating that the patient’s own immune cells (neutrophils) may actively help the process of metastasis by which the cancer spreads.
ANGLE plc (AIM: AGL and OTCQX: ANPCY), a world-leading liquid biopsy company, today announces its unaudited interim financial results for the six months ended 31 October 2018.